Introduction:
A controlled pilot study investigated the telomerase activator TA-65® in elderly patients following a heart attack. The focus was on changes in inflammatory markers and immune parameters, as well as whether any differences could be observed compared to a placebo group.
What was investigated in the study?
Blood levels were measured at the beginning of the study as well as after six and twelve months. In doing so, the researchers specifically examined inflammatory and immune parameters.
The researchers conducted a controlled pilot study with 90 patients aged 65 and older. The participants received either TA-65® or a placebo.
What results were observed?
According to the researchers, changes in certain inflammatory markers were observed in the TA-65® group. For one investigated inflammatory parameter, the study reported a reduction of up to 62%.
In addition, changes in certain immune parameters were described. The results provide indications that the activation of telomerase could be of scientific interest in this context for inflammatory and immune processes.
However, since this is a pilot study with 90 participants, no general conclusions regarding the treatment or prevention of cardiovascular diseases can be drawn from it.
How should the results be interpreted?
The investigation provides initial clinical data on TA-65® in elderly people after a heart attack. Due to the limited number of participants and the pilot nature of the study, the results should be interpreted with caution.
Larger clinical studies and longer observation periods are required to confirm the observed changes and to assess their potential clinical significance.
Original publication
To the scientific publication →
